imtesty, with all due respect, can you please expand on your statement?

"I could be wrong but it seems like RVX did go far as proof of concept; it was a great spokes-drug for the promise of BET inhibition, but has both lost its lead and been overtaken by other compounds for many saleable indications." (my bolding)

You say that RVX a BET inhibition drug has both lost its lead and been overtaken by other compounds for many saleable indications. Are you specifically referring to Apabetalone? And what other compounds are you referring to that have overtaken Apabetalone for many saleable indications if this is what you are saying? 

I wonder if Bear agrees with your statement.

TIA ... Koo